Genomic mapping of mutations in paediatric cancers
We want to enable development of new targeted treatments so more children survive cancer. Clinical validation of a new and promising genetic test for children will identify those most likely to benefit from novel targeted therapies based on the molecular make-up of each child’s tumour.
October 2015 - September 2016
Frontline treatment for children with cancer is old and comprises in the main chemotherapy drugs with an average age of 50 years along with radiotherapy and/or surgery. Often the outcome is not what is wanted and even when a child survives there is a legacy of longterm permament issues which impact on quality of life both for the child and for the family as a whole. For some children there is no current treatment offered and the only option is palliative care from the moment of diagnosis.
Technology and scientific knowledge have progresssd to the extent that new targeted treatments (already in use for some adult diseases) are starting to enter trials for children. We now understand genetic mutations from sequencing and are starting to offer trials with new treatments targeting these mutations. This research means that for those children for whom there was little or no hope of survival, we are beginnig to find treatments which impact upon their tumours and may change the outcome.
Sequencing of children's tumours to enable implementation of precision medicine clinical trials.
Activities» Generate a comprehensive genomic classification of paediatric solid tumours using targeted sequencing.
» Investigate the value of circulating biomarker analysis through targeted sequencing.
By the end of the project new data for children's tumours will be recorded. Children will be offered new trials specific to their needs based on the tumour biology.
Children will be offered new trials with a chance of new potential life saving treatments for those cancers against which current treatments have little or no long term positive effect. Success will be greater rates of survival for children with cancer, especially in the areas of current high mortality.
If the researcher leaves the role, the work would be transfeered to a new researcher.
Aspects of the work may need ethical approval. We would ensure that any submission to an ethics committee would be reviewd by a senior person at the research centre.
Donors will be kept updated through our quarterly newsletters, media reports and through our social media channels.
Budget - Project Cost: £38,750Loading graph....
Amount Heading Description £4,223 Fees Feat for Feet event £21,630 Stipend Donations and supporter fundraising £12,897 Consumables The Big Give
Current Funding / Pledges
Source Amount Christopher's Smile events and supporters £25,853 Guaranteed
The research will take place at The Instiute of Cancer Research in Sutton, Surrey. The ICR is part of London University.
Children with cancer across the UK for whom current treatments hold no or little hope of survival. In the longer term, the work will be extended across Europe.
Christopher's Smile funds only innovative research specifically into finding new safe and effective treatments for children with cancer. We set the charity up after the death of our only child aged 5 years to an aggresive brain tumour and we know first hand how it feels as a parent to be told that your child has no chance of surviving this cruel disease. We have one goal - to make a difference for children with cacer by helping to bring to the fore new safe and effective treatments.
Read more about the Charity running this project.
Elisa is the researcher who has been funded already by Christopher's Smile who developed the sequencing panel to be used in this ongoing work.